Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication.
Authors
Greystoke, AlastairHarris, G
Jenkins, M
Goonetilleke, D
Moore, David
Lancashire, Matthew
Ranson, Malcolm R
Hughes, A
Clack, G
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK; School of Cancer and Enabling Sciences, University of Manchester, Manchester, UK. Electronic address: agreystoke@picr.man.ac.uk.Issue Date
2013-06-21
Metadata
Show full item recordAbstract
There is increasing use of circulating cell death biomarkers in patients and clinical trials. Knowledge of the potential noise and confounders in assays are vital for biomarker interpretation. The daily and diurnal variability and effect of menstruation and exercise on nucleosomal DNA (nDNA), total cytokeratin 18 (tK18) and apoptotic specific cytokeratin 18 (cK18) were assessed in 3 cohorts of healthy volunteers; 12 pre-menopausal women to establish the effect of menstruation, 12 men to perform exercise and 12 post-menopausal women. All 36 subjects were evaluated to establish daily and diurnal variability. Estimates of variability were derived in a linear mixed effects model and presented as the back transformed coefficient of variation (%CV). Minimal variation was seen in cK18 (11%CV) and tK18 (11%CV) but higher variability was seen in nDNA (85%CV). K18 results appeared stable throughout the day but a possible peak in nDNA was seen at 15:00. Menstruation had minimal effects but exercise led to immediate short-lived elevations in cell death biomarkers. There is no evidence of significant daily variability in K18 assays. We recommend subjects should not exercise for 6h before blood sampling.Citation
Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication. 2013, 84C:184-188 J Pharm Biomed AnalJournal
Journal of Pharmaceutical and Biomedical AnalysisDOI
10.1016/j.jpba.2013.06.010PubMed ID
23838085Type
ArticleLanguage
enISSN
1873-264Xae974a485f413a2113503eed53cd6c53
10.1016/j.jpba.2013.06.010
Scopus Count
Collections
Related articles
- Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
- Authors: Linder S, Olofsson MH, Herrmann R, Ulukaya E
- Issue date: 2010 Apr
- A pilot study assessing the prognostic value of CK18 and nDNA biomarkers in severe sepsis patients.
- Authors: Moore DJ, Greystoke A, Butt F, Wurthner J, Growcott J, Hughes A, Dive C
- Issue date: 2012 Mar 1
- Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.
- Authors: Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S
- Issue date: 2007 Jun 1
- Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas.
- Authors: Brandt D, Volkmann X, Anstätt M, Länger F, Manns MP, Schulze-Osthoff K, Bantel H
- Issue date: 2010 May
- Soluble cytokeratin 18 biomarkers may provide information on the type of cell death during early ischemia and reperfusion periods of liver transplantation.
- Authors: Ulukaya S, Ulukaya E, Alper I, Yilmaztepe-Oral A, Kilic M
- Issue date: 2010 Nov-Dec